Nivolumab in renal transplant recipients with poor prognosis cancers - a safety study
Latest Information Update: 13 Jul 2022
At a glance
- Drugs Nivolumab (Primary)
- Indications Breast cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions
- 06 Jul 2022 Results published in the Lancet Oncology
- 25 Feb 2022 Actual date of last participant enrolled is 6 Aug 2021 according to Australian New Zealand Clinical Trials Registry record.
- 25 Feb 2022 Status changed from recruiting to completed.